Standards For Molecular Imaging Agents Can Vary, Panel Tells FDA
The evidence needed to show efficacy and utility of a molecular imaging agent depends on what is being scanned and what claim is being sought, FDA's Peripheral and Central Nervous System Drugs Advisory Committee advised the agency Aug. 11
You may also be interested in...
Autopsy is the gold standard for confirming a diagnosis of Alzheimer's disease and should be used as the standard of truth in studies of imaging agents hoping to gain approval for amyloid plaque detection, an FDA panel unanimously concluded
Nycomed Amersham's nuclear imaging agent Datscan has been recommended to distinguish Parkinson's disease from other disorders by the European Medicines Evaluation Agency's Committee for Proprietary Medicinal Products.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011